共 50 条
- [11] BAY 1143269, a novel MNK1 inhibitor, targets oncogenic protein expression and shows potent anti-tumor activityCANCER LETTERS, 2017, 390 : 21 - 29Santag, SusannSiegel, FranziskaWengner, Antje M.Lange, ClaudiaBoemer, UlfEis, KnutPuehler, FlorianLienau, PhilipBergemann, LindaMichels, Martinvon Nussbaum, FranzMumberg, DominikPetersen, Kirstin
- [12] Design, synthesis and activity of Mnk1 and Mnk2 selective inhibitors containing thieno[2,3-d]pyrimidine scaffoldEUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 162 : 735 - 751Jin, XinMerrett, JamesTong, ShengFlower, BartholomewXie, JianlingYu, RileiTian, ShuyeGao, LingZhao, JiajunWang, XueminJiang, TaoProud, Christopher G.
- [13] A phase 1 dose escalation study of eFT508, an inhibitor of mitogenactivated protein kinaseinteracting serinefthreonine kinase-1 (MNK-1) and MNK-2 in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Falchook, Gerald StevenInfante, Jeffrey R.Meric-Bernstam, FundaMiller, Langdon L.Morison, KarenVallner, DebraSperry, SamGoel, VikasChiang, Gary GeneWebster, KevinBarton, JeremyPatel, Manish R.
- [14] eFT508, a Potent and Selective Mitogen-Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 Inhibitor, Is Efficacious in Preclinical Models of Diffuse Large B-Cell Lymphoma (DLBCL)BLOOD, 2015, 126 (23)Webster, Kevin R.Goel, Vikas K.Hung, Ivy N. J.Parker, Gregory S.Staunton, JocelynNeal, MelissaMolter, JoleneChiang, Gary G.Jessen, Katti A.Wegerski, Christopher J.Sperry, SamuelHuang, VeraChen, JoanThompson, Peggy A.Appleman, James R.Webber, Stephen E.Sprengeler, Paul A.Reich, Siegfried H.
- [15] Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) InhibitionJOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (08) : 3516 - 3540Reich, Siegfried H.Sprengeler, Paul A.Chiang, Gary G.Appleman, James R.Chen, JoanClarine, JeffEam, BorethErnst, Justin T.Han, QingGoel, Vikas K.Han, Edward Z. R.Huang, VeraHung, Ivy N. J.Jemison, AdriannaJessen, Katti A.Molter, JoleneMurphy, DouglasNeal, MelissaParker, Gregory S.Shaghafi, MichaelSperry, SamuelStaunton, JocelynStumpf, Craig R.Thompson, Peggy A.Tran, ChinhWebber, Stephen E.Wegerski, Christopher J.Zheng, HongWebster, Kevin R.
- [16] Semaglutide as a potent activator of anti-tumor immune response in breast cancerEUROPEAN JOURNAL OF IMMUNOLOGY, 2024, 54 : 748 - 748Stanisavljevic, IsidoraJovanovic, IvanMarkovic, Bojana SimovicCorovic, IrfanKrajnovic, TamaraMijatovic, SanjaPavlovic, Sladjana
- [17] Inhibition of Growth of TSC2-Null Cells by a PI3K/mTOR Inhibitor but Not by a Selective MNK1/2 InhibitorBIOMOLECULES, 2020, 10 (01)Evans, Jilly F.Rue, Ryan W.Mukhitov, Alexander R.Obraztsova, KseniyaSmith, Carly J.Krymskaya, Vera P.
- [18] Discovery of a Selective and Potent Inhibitor of Mitogen-Activated Protein Kinase-Interacting Kinases 1 and 2 (MNK1/2) Utilizing Structure-Based Drug DesignJOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (07) : 3034 - 3045Han, WooseokDing, YuXu, YongjinPfister, KeithZhu, ShejinWarne, BobDoyle, MikeAikawa, MinaAmiri, PaymanAppleton, BrentStuart, Darrin D.Fanidi, AbdallahShafer, Cynthia M.
- [19] Discovery of indazole-pyridinone derivatives as a novel class of potent and selective MNK1/2 kinase inhibitors that protecting against endotoxin-induced septic shockEUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 213Dreas, AgnieszkaKucwaj-Brysz, KatarzynaPyziak, KarolinaKulesza, UrszulaWincza, EwelinaFabritius, Charles-HenryMichalik, KingaGabor-Worwa, EwelinaGolas, AnielaMilik, MariuszMasiejczyk, MagdalenaMajewska, ElizaPysniak, KazimieraWojcik-Trechcinska, UrszulaSandowska-Markiewicz, ZuzannaBrzozka, KrzysztofOstrowski, JerzyRzymski, TomaszMikula, Michal
- [20] A highly potent HPK1 inhibitor augments immune cell activation and anti-tumor immunity in a syngeneic tumor mouse modelMOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)Liu, HaoWu, LeiFeng, SongHuang, WeiLi, HuijuanLin, JingLiu, YangyangMei, LiufengRen, BaoqiXie, JulieYao, LiliZhong, Wenge